Regencell Bioscience Files Interim Financials for Dec 31, 2024

Ticker: RGC · Form: 6-K · Filed: 2025-06-30T00:00:00.000Z

Sentiment: neutral

Topics: financial-reporting, interim-results, sec-filing

TL;DR

Regencell 6-K filed: interim financials for 6 months ending Dec 31, 2024. Check financials.

AI Summary

Regencell Bioscience Holdings Limited has filed a Form 6-K on June 30, 2025, to furnish its unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for the six months ended December 31, 2024. This filing is made pursuant to Nasdaq Rule 5250(c)(2).

Why It Matters

This filing provides investors with an update on Regencell's financial performance and position as of the end of 2024, allowing for assessment of the company's operational health.

Risk Assessment

Risk Level: low — This filing is a routine submission of financial information and does not contain new material events or significant financial changes.

Key Players & Entities

FAQ

What specific financial statements are being furnished in this Form 6-K?

The unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for the six months ended December 31, 2024, are being furnished.

Under which rule is Regencell Bioscience Holdings Limited furnishing this information?

The information is being furnished pursuant to Nasdaq Rule 5250(c)(2).

What is the reporting period covered by the furnished financial statements?

The reporting period is the six months ended December 31, 2024.

Is this filing an annual report or an interim report?

This filing is a Form 6-K, which is a report of foreign private issuers and is used to furnish interim financial information.

What is the filing date of this Form 6-K?

The Form 6-K was filed on June 30, 2025.

From the Filing

0001213900-25-059287.txt : 20250630 0001213900-25-059287.hdr.sgml : 20250630 20250630090012 ACCESSION NUMBER: 0001213900-25-059287 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250630 DATE AS OF CHANGE: 20250630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regencell Bioscience Holdings Ltd CENTRAL INDEX KEY: 0001829667 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40617 FILM NUMBER: 251088892 BUSINESS ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 BUSINESS PHONE: 852 2155 0823 MAIL ADDRESS: STREET 1: 11/F FIRST COMMERCIAL BUILDING STREET 2: 33-35 LEIGHTON ROAD, CAUSEWAY BAY CITY: HONG KONG STATE: K3 ZIP: 999077 6-K 1 ea0247262-6k_regencell.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-40617 Regencell Bioscience Holdings Limited 9/F, Chinachem Leighton Plaza 29 Leighton Road Causeway Bay, Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INFORMATION CONTAINED IN THIS FORM 6-K REPORT Pursuant to Nasdaq Rule 5250(c)(2), Regencell Bioscience Holdings Limited (the “Company”) hereby furnishes its unaudited condensed consolidated interim balance sheets and statement of operations and comprehensive loss for its six months ended on December 31, 2024, which are attached as Exhibit 99.1 to this Form 6-K. Exhibit No. Description of Exhibit 99.1 Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 30, 2025 Regencell Bioscience Holdings Limited By: /s/ Yat-Gai Au Name: Yat-Gai Au Title: Chief Executive Officer and Chairman of the Board of Directors 2 EX-99.1 2 ea024726201ex99-1_regencell.htm REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES FIRST HALF 2025 MANAGEMENT FINANCIAL RESULTS Exhibit 99.1 Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results HONG KONG, June 30, 2025 – Regencell Bioscience Holdings Limited (Nasdaq: RGC) (the “Company”) today announced its unaudited condensed consolidated interim financial results for the six months ended December 31, 2024. UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 UNAUDITED CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS As of December 31, As of June 30, 2024 2024 Current assets $ 6,586,450 $ 8,114,013 Other assets 892,741 324,198 Total assets 7,479,191 8,438,211 Total liabilities 763,839 219,512 Total shareholders’ equity 6,715,352 8,218,699 Total liabilities and shareholders’ equity $ 7,479,191 $ 8,438,211 UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Six Months Ended December 31, 2024 2023 OPERATING EXPENSES: Selling and marketing expenses $ 7,329 $ 97,062 General and administrative expenses (including share-based compensation of approximately $0.2 million and $0.3 million for the six months ended December 31, 2024 and 2023 respectively) 1,463,125 1,730,043 Research and development expenses (including share-based compensation of approximately $0.08 million and reversal of share-based compensation of approximately $0.1 million for the six months ended December 31, 2024 a

View on Read The Filing